Biomarin Pharmaceutical (BMRN) Cash from Operations (2009 - 2026)
Biomarin Pharmaceutical's (BMRN) quarterly Cash from Operations came in at 220651000.0 in Q1 2026, up 26.52% YoY from 174394000.0 in Q1 2025, and up 121.44% on a QoQ basis from 99644000.0 in Q4 2025.
Biomarin Pharmaceutical (BMRN) Cash from Operations (2009 - 2026) Analysis & Trends
Biomarin Pharmaceutical (BMRN) has 18 years of Cash from Operations data on file, last reported at 220651000.0 in Q1 2026.
- Quarterly Cash from Operations rose 26.52% year-over-year to 220651000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 874251000.0 (up 24.85% YoY) and the FY2025 annual result came in at 827994000.0, up 44.54% from the prior year.
- Cash from Operations improved to 220651000.0 in Q1 2026, from 99644000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 368685000.0 in Q3 2025 to a low of 73932000.0 in Q1 2023.
- A 5-year average of 115096882.35 and a median of 118762000.0 in 2024 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2022 — Cash from Operations plunged 140.02% — and 2024, when it surged 575.42%.
- Tracing BMRN's Cash from Operations over 5 years: stood at 6786000.0 in 2022, then soared by 305.0% to 27483000.0 in 2023, then surged by 575.42% to 185627000.0 in 2024, then tumbled by 46.32% to 99644000.0 in 2025, then surged by 121.44% to 220651000.0 in 2026.
- The last three Cash from Operations figures came in at 220651000.0 (Q1 2026), 99644000.0 (Q4 2025), and 368685000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Biomarin Pharmaceutical | 13.04 Bn | 12.16 Bn | 786.91 Mn | 168.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 168.11 Mn |
| Jun 30, 2026 | 168.11 Mn |
| Mar 31, 2026 | 220.65 Mn |
| Mar 31, 2026 | 220.65 Mn |
| Dec 31, 2025 | 99.64 Mn |
| Dec 31, 2025 | 99.64 Mn |
| Sep 30, 2025 | 368.69 Mn |
| Sep 30, 2025 | 368.69 Mn |
| Jun 30, 2025 | 185.27 Mn |
| Jun 30, 2025 | 185.27 Mn |
| Mar 31, 2025 | 174.39 Mn |
| Mar 31, 2025 | 174.39 Mn |
| Dec 31, 2024 | 185.63 Mn |
| Dec 31, 2024 | 185.63 Mn |
| Sep 30, 2024 | 221.48 Mn |
| Sep 30, 2024 | 221.48 Mn |
| Jun 30, 2024 | 118.76 Mn |
| Jun 30, 2024 | 118.76 Mn |
| Mar 31, 2024 | 46.97 Mn |
| Mar 31, 2024 | 46.97 Mn |